Antihypertensive Drug Use and COVID‐19 Disease Severity in Hospitalized US Veterans: A Retrospective Cohort Study

Fuente: Wiley Open Access
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Merodean Huntsman, Jessica L. Marquez, Gregory J. Stoddard, Guo Wei, Aaron J. Miller, Jayant P. Agarwal, Sujee Jeyapalina
Format: Artículo Open Access
Veröffentlicht: Wiley 2025
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1867018599569293312
author Merodean Huntsman
Jessica L. Marquez
Gregory J. Stoddard
Guo Wei
Aaron J. Miller
Jayant P. Agarwal
Sujee Jeyapalina
author_facet Merodean Huntsman
Jessica L. Marquez
Gregory J. Stoddard
Guo Wei
Aaron J. Miller
Jayant P. Agarwal
Sujee Jeyapalina
Merodean Huntsman
Jessica L. Marquez
Gregory J. Stoddard
Guo Wei
Aaron J. Miller
Jayant P. Agarwal
Sujee Jeyapalina
collection Wiley Open Access
contents Antihypertensive Drug Use and COVID‐19 Disease Severity in Hospitalized US Veterans: A Retrospective Cohort Study Merodean Huntsman Jessica L. Marquez Gregory J. Stoddard Guo Wei Aaron J. Miller Jayant P. Agarwal Sujee Jeyapalina The Journal of Clinical Hypertension ABSTRACTThis research investigated associations between hypertensive patients with COVID‐19 who did and did not use specific antihypertensive medications and had incurred hospital ventilation/death in the US Veterans Hospital System. This study included de‐identified medical records of 572 994 hypertensive US veterans who were diagnosed with COVID‐19 and hospitalized between March 1, 2020, and February 28, 2022, with a 60‐day follow‐up period. Mechanical ventilation and/or death within 60 days of COVID‐19 hospitalization served as the outcome variables. On multivariable analysis, CCB use was associated with a 9% increased risk of mechanical ventilation, while ACE inhibitors (HR: 0.90), alpha blockers (HR: 0.92), and CCB (HR: 0.93) users were associated with a significantly decreased risk of death. Additional multivariable analysis on those with and without additional comorbidities, such as chronic kidney disease (CKD), heart failure, and diabetes, revealed that in those with at least one additional comorbidity, CCB uses led to a 9% increased deleterious risk for ventilation. In contrast, the use of ACE inhibitors (HR: 0.86), alpha blockers (HR: 0.92), and CCB (HR: 0.93) demonstrated a moderate protective effect against mortality. Lastly, in hypertensive veterans without any additional comorbidities, there was a lack of significant association between hypertensive medication usage and mechanical ventilation and/or death. In summary, although CCB use was associated with an increased risk of requiring mechanical ventilation, it also demonstrated a protective effect against mortality. At the same time, ACEI, alpha blocker, and CCB usage led to a significantly decreased risk for death within all hypertensive hospitalized COVID‐19 veteran cohorts. 10.1111/jch.70021 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1111/jch.70021
format Artículo Open Access
id wiley_oa_10_1111_jch_70021
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Antihypertensive Drug Use and COVID‐19 Disease Severity in Hospitalized US Veterans: A Retrospective Cohort Study
Merodean Huntsman
Jessica L. Marquez
Gregory J. Stoddard
Guo Wei
Aaron J. Miller
Jayant P. Agarwal
Sujee Jeyapalina
The Journal of Clinical Hypertension
Antihypertensive Drug Use and COVID‐19 Disease Severity in Hospitalized US Veterans: A Retrospective Cohort Study Merodean Huntsman Jessica L. Marquez Gregory J. Stoddard Guo Wei Aaron J. Miller Jayant P. Agarwal Sujee Jeyapalina The Journal of Clinical Hypertension ABSTRACTThis research investigated associations between hypertensive patients with COVID‐19 who did and did not use specific antihypertensive medications and had incurred hospital ventilation/death in the US Veterans Hospital System. This study included de‐identified medical records of 572 994 hypertensive US veterans who were diagnosed with COVID‐19 and hospitalized between March 1, 2020, and February 28, 2022, with a 60‐day follow‐up period. Mechanical ventilation and/or death within 60 days of COVID‐19 hospitalization served as the outcome variables. On multivariable analysis, CCB use was associated with a 9% increased risk of mechanical ventilation, while ACE inhibitors (HR: 0.90), alpha blockers (HR: 0.92), and CCB (HR: 0.93) users were associated with a significantly decreased risk of death. Additional multivariable analysis on those with and without additional comorbidities, such as chronic kidney disease (CKD), heart failure, and diabetes, revealed that in those with at least one additional comorbidity, CCB uses led to a 9% increased deleterious risk for ventilation. In contrast, the use of ACE inhibitors (HR: 0.86), alpha blockers (HR: 0.92), and CCB (HR: 0.93) demonstrated a moderate protective effect against mortality. Lastly, in hypertensive veterans without any additional comorbidities, there was a lack of significant association between hypertensive medication usage and mechanical ventilation and/or death. In summary, although CCB use was associated with an increased risk of requiring mechanical ventilation, it also demonstrated a protective effect against mortality. At the same time, ACEI, alpha blocker, and CCB usage led to a significantly decreased risk for death within all hypertensive hospitalized COVID‐19 veteran cohorts. 10.1111/jch.70021 http://creativecommons.org/licenses/by/4.0/
title Antihypertensive Drug Use and COVID‐19 Disease Severity in Hospitalized US Veterans: A Retrospective Cohort Study
topic The Journal of Clinical Hypertension
url https://onlinelibrary.wiley.com/doi/10.1111/jch.70021